# **Microscopic Colitis**

## **Background**

- 1. Definition
  - Chronic inflammatory bowel dz encompassing both lymphocytic colitis and collagenous colitis<sup>1</sup>
- 2. General info
  - Collagenous colitis
    - Thickening of subepithelial basement membrane of colonic mucosa w/a band of collagen
  - o Lymphocytic colitis
    - Intraepithelial lymphocytosis w/o collagen thickening

# **Pathophysiology**

- 1. Pathology of dz
  - Not completely known
  - o Normal radiologic and colonoscopic appearance of colon
  - Abnormal histologic appearance of colon
  - o Leads to chronic watery diarrhea w/o bleeding
- 2. Incidence/ prevalence
  - o Incidence of 10 per 100,000 person-yrs
    - Lymphocytic: 5.4 per 100,000
    - Collagenous: 4.6 per 100,000<sup>2</sup>
  - o Prevalence of 103 per 100,000 person-yrs
    - Lymphocytic: 63.7 per 100,000
    - Collagenous: 39.3 per 100,000
- 3. Risk factors
  - o Pt characteristics<sup>2</sup>
    - Older age
    - Female
  - Assoc autoimmune dz<sup>4</sup>
    - Hypothyroidism
    - Celiac dz
    - Diabetes mellitus
    - Rheumatoid arthritis
    - Asthma
    - Allergies
- 4. Morbidity/mortality
  - Not assoc w/incr mortality or severe deterioration
  - o No incr risk of neoplasia

## **Diagnostics**

- 1. History
  - o Intermittent, chronic, non-bloody, watery diarrhea
  - o Diarrhea up to 2 L or 4-9 episodes/d
  - Vague abdominal pain
  - Fecal urgency
  - Wt loss

- o Fatigue
- o Nausea
- 2. Physical exam
  - Unremarkable
  - Vague abdominal tenderness
  - Wt loss
- 3. Diagnostic testing
  - Laboratory evaluation
    - ESR may show slight elevation
    - Autoantibodies found in half of pts
      - RF, ANA, antimitochondrial antibodies, and anti-neutrophil cytoplasmic antibodies
    - Tissue transglutaminase antibody or antiendomysium antibody to rule out celiac dz
    - Stool culture to rule out infectious cause
    - Incr levels of stool inflammatory markers
      - Eosinophil protein X, myeloperoxidase, and tryptase
  - Diagnostic imaging
    - Normal radiologic appearance of colon
  - Other studies
    - Normal colonoscopic appearance of colon
    - Colon biopsy for Dx
      - Number and location of biopsies not established
      - Proximal biopsies improve sensitivity

#### Differential Dx

- 1. Key DDx
  - Irritable bowel syndrome
  - Ulcerative colitis
  - o Crohn's dz
  - o Diverticulitis
  - o Ischemic colitis
  - Drug-induced colitis
  - Infectious colitis
  - Lactose intolerance
  - o Celiac dz
- 2. Extensive DDx
  - Hyperthyroidism
  - o Carcinoid syndrome
  - o VIPoma
  - Colon cancer
  - o Other causes of abdominal pain and chronic diarrhea

## **Therapeutics**

- 1. Reassure pt:
  - Dz has not been assoc w/colonic neoplasia, incr mortality, or severe deterioration
- 2. Discontinue any offending drugs

- 3. Budesonide
  - o Start at 9 mg/d for 4 wk
  - o Treat over a 6-8 wk period
  - o If in remission
    - Taper to 6 mg for 2 wk
    - Then 3 mg for 2 wk
    - Then discontinue
  - May continue dose of 9 mg/d for 12 wks before tapering if Sx are not controlled or if Sx recur on tapering<sup>7,8</sup>
- 4. Bismuth subsalicylate
  - Nine 262 mg tablets daily in 3 divided doses for 8 wk trial is reasonable in pt w/collagenous colitis<sup>7</sup>
- 5. Mesalamine
  - o 800 mg TID w/or w/o cholestyramine
  - 4 g daily may be effective for pts w/active collagenous or lymphocytic colitis<sup>7,8</sup>
- 6. Loperamide
  - o May be used for symptomatic Tx of diarrhea
- 7. Boswellia serrata extract, prednisolone and probiotics
  - No evidence on effectiveness
- 8. Surgery
  - Rarely recommended or reported
  - Ileostomy may be procedure of choice in older pts w/severe, resistant disorder

## Follow-Up

- 1. Return to office
  - As needed if not responding to Tx
- 2. Refer to specialist
  - Not indicated unless refractory to Tx
- 3. Admit to hospital
  - o Only if unable to manage as outpatient (rare)

#### **Prognosis**

- 1. Dz course variable w/alternating remissions and relapses
  - Good long-term prognosis
- 2. Not assoc w/incr mortality or severe deterioration
- 3. 80% resolve spontaneously in less than 3 yrs<sup>5</sup>
- 4. Recurrence is common despite Tx<sup>9</sup>
- 5. No incr risk of neoplasia

## **Prevention**

- 1. Limit drugs assoc w/dz
- 2. Limit dietary factors that may exacerbate condition
  - o Caffeine, alcohol, dairy products

#### **Patient Education**

1. http://digestive.niddk.nih.gov/ddiseases/pubs/collagenouscolitis/

#### References

- 1. Sveinsson OA, Orvar KB, Birgisson S, Jonasson JG. Microscopic colitis review. Laeknabladid. 2008 May;94(5):363-70.
- 2. Williams JJ, Kaplan GG, Makhija S, Urbanski SJ, Dupre M, Panaccione R, Beck PL. Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol. 2008 Jan;6(1):35-40.
- 3. Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn WJ. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007 Apr;56:504 508.
- 4. Nyhlin N, Bohr J, Eriksson S, Tysk C. Systematic review: microscopic colitis. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1525-34.
- 5. Nielsen OH, Vainer B, Rask-Madsen J. Non-IBD and noninfectious colitis. Nat Clin Pract Gastroenterol Hepatol. 2008 Jan;5(1):28-39.
- 6. Beaugerie L; Pardi DS. Review article: drug-induced microscopic colitis proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005 Aug 15;22(4):277-84.
- 7. Chande N, McDonald JW, Macdonald JK. Interventions for treating collagenous colitis. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003575.
- 8. Chande N, McDonald JW, Macdonald JK. Interventions for treating lymphocytic colitis. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006096.
- 9. Nyhlin N, Bohr J, Eriksson S, Tysk C. Microscopic colitis: a common and an easily overlooked cause of chronic diarrhoea. Eur J Intern Med. 2008 May;19(3):181-6.

Author: Matthew Short, MD, Madigan Army FMR, Fort Lewis, WA

Editor: Charles Webb, DO, Oregon Health & Sciences University